# Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT03583424** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Hematopoietic Cell Transplantation Recipient
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Transformed Indolent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **PROCEDURE:** Hematopoietic Cell Transplantation
- **DRUG:** Melphalan
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03583424
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-10
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583424, "Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03583424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*